Oncolytic viruses (OVs) are powerful new therapeutic agents in cancer therapy. With the first
OV (talimogene laherparepvec [T-vec]) obtaining US Food and Drug Administration …

Since the discovery in 1796 by Edward Jenner of vaccinia virus as a way to prevent and
finally eradicate smallpox, the concept of using a virus to fight another virus has evolved into …

The large coding potential of vaccinia virus (VV) vectors is a defining feature. However,
limited regulatory switches are available to control viral replication as well as timing and …

As a promising therapeutic strategy, oncolytic virotherapy has shown potent anticancer
efficacy in numerous pre-clinical and clinical trials. Oncolytic viruses have the capacity for …

Introduction: Metastatic cancers are extremely difficult to treat, and account for the vast
majority of cancer-related deaths. The dissemination of tumor cells to distant sites is highly …

The fusion of muscle precursor cells is a required event for proper skeletal muscle
development and regeneration. Numerous proteins have been implicated to function in …

According to the World Health Organization, cancer is one of the leading global health
concerns, causing nearly 10 million deaths in 2020. While classical chemotherapeutics …

Modern oncotherapy approaches are based on inducing controlled apoptosis in tumor cells.
Although a number of apoptosis-induction approaches are available, site-specific delivery of …

Background Oncolytic viruses reduce tumor burden in animal models and have generated
promising results in clinical trials. However, it is likely that oncolytic viruses will be more …

Vesicular stomatitis virus (VSV), a negative-strand RNA virus of the Vesiculovirus genus, has
demonstrated encouraging anti-neoplastic activity across multiple human cancer types. VSV …